|
|
||||||||
1 Baker Medical Research Institute, Melbourne, Victoria 8008, Australia; and 2 Department of Kinesiology and Applied Physiology, University of Colorado, Boulder, Colorado 80309
| |
ABSTRACT |
|---|
|
|
|---|
Investigating aging effects on the sympathetic nervous system and ascertaining underlying central nervous system (CNS) mechanisms mediating sympathetic stimulation is clinically pertinent because of the possible interconnection of cardiovascular disease development with age-dependent sympathetic nervous changes. Because of previous evidence linking human CNS neuronal noradrenergic function and sympathetic activity, we investigated the influence of aging on brain norepinephrine turnover in 22 healthy men aged 20-30 yr and 16 healthy men aged 60-75 yr by measuring the internal jugular venous overflow of norepinephrine and its lipophilic metabolites. Sympathoneural and adrenal medullary function was also studied, using plasma catecholamine isotope dilution methodology and regional central venous sampling. In the older men there was increased norepinephrine turnover in suprabulbar subcortical brain regions, 317 ± 50 ng/min compared with 107 ± 18 ng/min in younger men. A differentiated sympathetic nervous activation was also present in older men. Overall, levels of both cardiac and hepatomesenteric norepinephrine spillover were directly correlated with subcortical norepinephrine turnover. These findings suggest that in sympathetic nervous activation accompanying aging, as has previously been demonstrated with the sympathetic nervous stimulation in human hypertension and heart failure, there is an underlying sympathoexcitatory influence of noradrenergic projections to suprabulbar subcortical regions.
epinephrine; heart; kidneys; adrenal medulla
| |
INTRODUCTION |
|---|
|
|
|---|
THE FUNCTION OF THE HUMAN sympathetic nervous system is altered in important ways by aging. These changes involve both the properties of the adrenergic receptors and the outflow of sympathetic neural traffic to individual organs (32). Based in large part on subcutaneous multiunit microneurographic recording from sympathetic fibers distributed in the company of motor nerves (1, 28, 37) and on the measurement of the spillover of the sympathetic neurotransmitter norepinephrine to plasma (14, 15, 36), there is now unequivocal evidence that progressive sympathetic activation occurs with aging. This sympathetic stimulation appears to involve the sympathetic outflow to the heart, the skeletal muscle vasculature, and the gut and liver, but to exclude the kidneys (14, 15). The nature of the underlying disturbance in central nervous system (CNS) sympathetic control, however, remains unknown.
The impetus for seeking to better understand the central nervous mechanisms by which aging causes sympathetic activation has come in part from recognition that in a variety of cardiovascular disorders, including cardiac failure, essential hypertension, and ventricular arrhythmias, for all of which incidence rises with age, the sympathetic nervous system is causally involved (11). Antiadrenergic drugs have come to occupy an important place in their treatment. Further analysis of both the effects of aging on sympathetic nervous system function and the CNS mechanisms mediating sympathetic stimulation becomes pertinent in this context of a possible interconnection of cardiovascular disease development with age-dependent changes in sympathetic nervous function.
In several clinical contexts, most notably cardiac failure and essential hypertension, we previously demonstrated the importance of projections of noradrenergic neurons to suprabulbar subcortical areas in generating the peripheral sympathetic nervous stimulation present (16, 22, 23). This contrasted with earlier experimental evidence that had documented a sympathetic suppressant rather than excitatory effect of noradrenergic neurons in the medulla oblongata mediated by the arterial baroreflex (4). In some clinical settings characterized by sympathetic nervous activation, most notably obesity, the central mechanism mediating sympathetic nervous activation also appears not to be noradrenergic. In human obesity, brain serotonin turnover is increased but norepinephrine turnover is normal (26).
The links that have been previously demonstrated between human suprabulbar subcortical human norepinephrine turnover and sympathetic activity were established by measuring CNS norepinephrine turnover, based on the overflow of norepinephrine and its lipophilic metabolites 3-methoyxy-4-hydroxyphenylglycol (MHPG) and dihydroxyphenylglycol (DHPG) into the internal jugular veins (16, 22, 23) in parallel with peripheral sympathetic activity, quantified by isotope dilution measurements of whole body and regional norepinephrine spillover to the circulation. In the present paper we apply these methods to investigate the sympathoneural changes accompanying healthy aging and the possible mediating CNS mechanisms.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Experimental subjects. Twenty-two men aged 20-30 yr and 16 aged 60-75 yr participated as research volunteers in the study. All were recruited from the general community by advertisement and found to be in good health. A comprehensive clinical evaluation was performed by a specialist physician in all experimental subjects, and testing included a chest X ray, hematology and multipanel serum biochemistry testing. All recruited volunteers were nonsmokers. None were obese; mean body mass index was 24.0 kg/m2 in the younger men and 24.9 kg/m2 in the older men. All subjects gave written informed consent for their participation in the study, which was approved by the Alfred Hospital Ethics Review Committee.
General procedure. All subjects were studied at rest in the supine position 2 h after eating a standardized light breakfast (16, 22). Tea, coffee, and alcohol were withheld for a minimum of 12 h before the study. Total body sympathetic function was assessed utilizing the principle of plasma norepinephrine isotope dilution (10). The overflow of norepinephrine and its metabolites from the brain into one or both internal jugular veins was also measured, to measure cerebral norepinephrine turnover (6, 22, 23). For this purpose blood samples for plasma catechol assay were obtained from a central venous catheter and a brachial arterial cannula. These were percutaneously inserted under local anesthesia. The central venous catheter, a 7-F coronary sinus thermodilution catheter (Webster Laboratories, type CCS-7U-90B), introduced via an antecubital venous sheath, was placed with fluoroscopic control high up in one or both internal jugular veins beyond the angle of the jaw to exclude sampling from the venous drainage of the tissues of neck and face (16, 22, 23). Jugular venous sampling was bilateral in seven younger and in five older men.
The central venous catheter was repositioned under fluoroscopic control to also allow blood sampling from the coronary sinus (25 subjects), the right hepatic vein (17 subjects), and the right renal vein (19 subjects). In each case the catheter position was verified with 2 ml radiopaque contrast medium (Omnipaque, Winthrop Pharmaceuticals). The right renal vein was used for renal sampling to avoid the contamination from adrenal venous drainage that occurs on the left (10). Arterial blood samples were obtained from the brachial artery simultaneously with venous sampling, using a percutaneously placed 21-gauge cannula. Throughout the catheter study tritiated norepinephrine was infused for the determination of plasma norepinephrine kinetics (10). Measurements of the spillover of norepinephrine to plasma from the heart, hepatomesenteric circulation, and kidneys, and from the body as a whole were used to estimate organ-specific and overall sympathetic nervous activity. The relationship that exists between the rate of sympathetic nerve firing in an organ and release of norepinephrine into its venous drainage provides the experimental justification for the use of transmitter spillover measurements in the study of sympathetic nervous function (10).Measurement of brain norepinephrine turnover. The estimate of brain norepinephrine turnover was based on the Fick principle, utilizing measurements of venoarterial plasma concentration differences for norepinephrine and the lipophilic norepinephrine metabolites MHPG and DHPG across the brain, with arterial and internal jugular venous sampling. The associated internal jugular blood and plasma flows were measured by thermodilution, with appropriate adjustment for the hematocrit (16, 22). Cerebral norepinephrine spillover was calculated using isotope dilution in plasma, whereas for DHPG and MHPG blood flow rather than plasma flow was used in the calculations, based on results showing that DHPG and MHPG added to whole blood are rapidly and equally distributed between plasma and the red cell compartment (25).
Brain norepinephrine turnover, as calculated, represented the combined jugular venous overflow of norepinephrine, DHPG, and MHPG (16, 22, 23). This overflow of norepinephrine, DHPG, and MHPG into the cerebrovascular circulation is thought to be primarily derived from the noradrenergic neurons of the brain rather than from the sympathetic innervation of the cerebral arterial blood vessels. The evidence justifying this viewpoint is the finding that ganglionic blockade with trimethaphan does not reduce calculated cerebral norepinephrine turnover, whereas in patients with pure autonomic failure, who have sympathetic nerve degeneration, transcerebral release of norepinephrine is undiminished (24).Cerebral venous sinus scan.
Differentiating the pattern of cerebral drainage into the internal
jugular veins was of crucial importance in the present study in
allowing selective measurement of suprabulbar subcortical norepinephrine turnover. Using a technetium-99 cerebral venous sinus
scan to delineate the pattern of venous drainage in individual subjects, one can distinguish subcortical and cortical
neurotransmitter turnover (Fig. 1)
(16, 22). The more common pattern is for the right
internal jugular vein to have the superior sagittal sinus as its major
tributary and the cerebral cortex as its predominant field of drainage;
here, suprabulbar subcortical venous drainage from regions such as the
hypothalamus and amygdala is into the left internal jugular vein.
Venous drainage from the medulla oblongata is primarily into the veins
of the spinal cord and dural venous sinuses, not the internal jugular
veins (18). Sometimes the venous sinus drainage pattern is
reversed, with cortical venous drainage being into the left internal
jugular vein. In a minority of cases, the drainage pattern is
nonlateralizing, with ready admixture of blood occurring at the
confluence of the sagittal and straight sinuses.
|
Measurement of total body norepinephrine spillover and clearance. The total body norepinephrine spillover rate and plasma norepinephrine clearance were measured using the radiotracer method developed in our laboratory (10). In brief, the method involves the continuous intravenous infusion of a tracer dose of norepinephrine (0.70 µCi/min levo-[7-3H]norepinephrine, specific activity 12-20 Ci/mmol, New England Nuclear, Boston, MA) to a steady-state concentration in plasma. The total norepinephrine spillover to plasma was derived from isotope dilution, and total plasma norepinephrine clearance from the plateau plasma concentration of tracer.
Cardiac, hepatomesenteric, and renal norepinephrine spillover.
The rate of norepinephrine spillover from the heart, hepatomesenteric
circulation, and kidneys was calculated according to the Fick principle
from regional isotope dilution and plasma flows using established
methods (10)
|
Measurement of the rate of epinephrine secretion.
With continuous intravenous infusion of a tracer dose of epinephrine
(0.5-1.0 µCi/min
levo-N-methyl-[3H]epinephrine, specific
activity 55-75 Ci/mmol, New England Nuclear), the rate of whole
body epinephrine secretion was measured by isotope dilution as
follows (10)
|
Assays of catechols and MHPG.
Arterial blood samples were transferred immediately to ice-chilled
tubes containing an anticoagulant and antioxidant (EGTA plus
glutathione). Plasma was separated by centrifugation at 4°C, and
samples were subsequently stored at
70°C until assayed. Endogenous norepinephrine, epinephrine, DHPG, and MHPG plasma concentrations were
measured by high performance liquid chromatography with electrochemical detection according to our previously published methods (25, 27). Fractions of the eluant leaving the electrochemical cell were collected into scintillation vials for measurement of
3H-labeled norepinephrine and epinephrine by liquid
scintillation spectroscopy.
Statistical methods.
Data are expressed as means ± SE. Testing for normality of the
data was performed with a
2 goodness-of-fit test and
tests for skewness and kurtosis (33). Between-group
comparisons were made using the Student's t-test for
normally distributed values and the Mann-Whitney U-test for non-Gaussian data. The null hypothesis was rejected at
P < 0.05.
| |
RESULTS |
|---|
|
|
|---|
Blood pressure, heart rate, and body mass index. Younger and older men had almost identical heart rates, 66 ± 3 beats/min (mean ± SE) compared with 67 ± 4 beats/min. Arterial systolic pressures were similar, 136 ± 3 mmHg in younger men and 144 ± 4 mmHg in older men (difference not statistically significant). The same applied for diastolic pressures, 76 ± 2 mmHg compared with 77 ± 3 mmHg. Mean body mass index also was similar in the two age groups, 24.0 kg/m2 in the younger men and 24.9 kg/m2 in the older men.
Cerebral norepinephrine turnover.
CNS norepinephrine turnover in the field of an internal jugular
drainage was estimated from the combined overflow of norepinephrine, MHPG, and DHPG into the internal jugular vein. Brain norepinephrine turnover in the 16 older men, based on all 21 unilateral internal jugular vein plasma samples (bilateral sampling in 5 older men), was
higher than in the 22 younger men (29 unilateral jugular venous plasma
samples), 231 ± 34 ng/min (mean ± SE), compared with
136 ± 19 ng/min (P < 0.05) (Table
1).
|
|
Whole body sympathetic activity.
The mean concentration of norepinephrine in arterial plasma was 49.7%
higher in the older than in the younger men, attributable to 27.5%
lower clearance of norepinephrine from plasma (P < 0.05) and a 7.2% higher rate of whole body spillover of norepinephrine to plasma (difference not statistically significant) (Table
3). Measures of whole body sympathetic
activity were unrelated to arterial blood pressures and heart rates
overall for both groups combined.
|
Epinephrine secretion rate. The mean plasma concentration of epinephrine was 27.3% lower in the older than the younger men (difference not statistically significant), consequent on a lower epinephrine secretion rate, 112 ± 6 ng/min (mean ± SE) vs. 248 ± 31 ng/min (P < 0.01), partially cancelled out by a lower plasma epinephrine plasma clearance, 1.98 ± 0.11 l/min compared with 2.87 ± 0.15 l/min (P < 0.01).
Cardiac sympathetic activity.
The spillover of norepinephrine from the heart to plasma was increased
in the older men, 28 ± 3 ng/min, compared with 18 ± 2 ng/min in the younger men (P < 0.05) (Table 3, Fig.
2). This difference was not a consequence
of hemodynamic influences on transmitter washout to the circulation, as
coronary sinus plasma flows were similar, but in addition to increased
cardiac sympathetic nerve firing, diminished neuronal reuptake of
norepinephrine may have contributed. The extraction of tritiated
norepinephrine from plasma during transit through the heart, which is
predominantly into cardiac sympathetic nerves (8, 10), was
lower in the older men: mean 72%, range 42-87%, compared with
mean 83%, range 60-92% (P < 0.05, Mann-Whitney
U-test). Cardiac norepinephrine spillover was unrelated to
resting heart rate overall for both groups combined.
|
Hepatomesenteric sympathetic activity.
Hepatomesenteric norepinephrine spillover was higher in the older men,
63 ± 13 ng/min compared with 29 ± 9 ng/min (Tables 3 and
4), providing evidence of increased
sympathetic tone in this vascular district. For hepatomesenteric
norepinephrine spillover measurements, however, there is a limitation
of the kinetic methodology as applied to a portal circulation. Because
hepatic artery and portal vein plasma flows are unknown and there is no
plasma sampling downstream from the intestines, in the portal vein, it
is not possible to ascertain whether increased "hepatomesenteric"
norepinephrine spillover derives from the gut, from the liver, or from
both (2, 3). Hepatomesenteric extraction of tritiated
norepinephrine was identical in younger and older men (Table 4), so
that as far as can be ascertained, the higher spillover of
norepinephrine into the hepatic vein is not attributable to lesser
extraction of norepinephrine by the liver.
|
Renal sympathetic activity. The renal norepinephrine plasma kinetics measurements provided some evidence against the development of generalized sympathetic activation with aging. Norepinephrine spillover from the kidneys, although ~40% higher in older men, did not differ significantly from that in younger men (Table 3).
Relationship of brain norepinephrine turnover to regional sympathetic tone and epinephrine secretion. The central neurotransmitter mechanisms of sympathetic nervous control, and any distortion with aging, may not be identical in all sympathetic outflows. We tested whether a relationship existed between suprabulbar subcortical CNS norepinephrine turnover and the neural outflow in individual regions, specifically the heart, hepatomesenteric circulation, kidneys, and adrenal medulla.
For all experimental subjects combined, a direct relationship of suprabulbar subcortical norepinephrine turnover to cardiac sympathetic activity was present; for subcortical norepinephrine turnover vs. cardiac norepinephrine spillover, r = 0.64, P < 0.05. For hepatomesenteric norepinephrine spillover and suprabulbar subcortical norepinephrine turnover, a direct relationship also existed: r = 0.57, P < 0.05. Renal norepinephrine spillover and subcortical norepinephrine turnover were unrelated. For epinephrine secretion, a nonsignificant negative relationship to subcortical brain norepinephrine turnover existed: r =
0.38, P > 0.05).
| |
DISCUSSION |
|---|
|
|
|---|
In several clinical contexts, most notably cardiac failure and essential hypertension, we previously demonstrated the probable importance of projections of noradrenergic neurons to the forebrain in generating the peripheral sympathetic nervous stimulation present (16, 22, 24). This contrasts with the earlier experimental evidence of a baroreflex-linked sympathetic suppressant effect of norepinephrine in the medulla (4). In the present study we found the sympathetic activity accompanying aging to be associated with increased suprabulbar subcortical turnover of norepinephrine. In healthy young men also, even within the rather narrow normal range of sympathetic activity present, there is a close positive relationship between norepinephrine turnover in suprabulbar subcortical brain areas and peripheral sympathetic activity (24).
That these relationships exist was established by measuring CNS norepinephrine turnover, based on the overflow of norepinephrine and its lipophilic metabolites MHPG and DHPG into the internal jugular veins. In pilot studies (unpublished observations), it was found that CNS norepinephrine turnover shows sexual dimorphism in humans. The combined overflow of norepinephrine, MHPG, and DHPG into the internal jugular veins was substantially higher in young women than in young men, and this higher brain norepinephrine turnover in women was unrelated to the level of sympathetic nervous activity present, which was no higher in women. The present study investigating the influence of aging on brain norepinephrine turnover was confined to men because of this confounding influence of gender on brain norepinephrine turnover.
This increased brain norepinephrine turnover noted in the elderly could possibly have originated from defective neuronal reuptake of norepinephrine, which would facilitate noradrenergic neurotransmission. In sympathetic nerves there is an age-related impairment in norepinephrine transporter action (14, 15). A reduction in brain neuronal reuptake of norepinephrine in the elderly, effected by reducing intraneuronal metabolism of norepinephrine and facilitating extraneuronal metabolism, might perhaps be expected to reduce DHPG jugular overflow into the internal jugular veins and increase MHPG overflow (21, 25), although there is disagreement on this point (7, 8). Our findings, however, argue against the importance of a central defect in neuronal norepinephrine reuptake. In the younger men the proportionality between jugular vein overflows of norepinephrine, DHPG, and MHPG was similar to that in older men, and the contribution of MHPG overflow to the estimated CNS norepinephrine turnover also was similar, 73% and 62%.
Our additional finding here, of a selective activation of the sympathetic nervous system with aging, involving the outflows to the heart and hepatomesenteric circulation accompanied by reduced adrenal medullary secretion of epinephrine, are in agreement with our previous studies (13-15). Prior clinical microneurographic measurements also document increased nerve traffic with aging in the postganglionic sympathetic fibers distributed to the skeletal muscle vasculature (1, 28, 32, 37). As in the earlier reports, we note no significant increase in the spillover of norepinephrine from the kidneys, suggesting that the renal sympathetic outflow is not activated with aging. In the present study, however, the number of observations made on renal norepinephrine spillover was insufficient for us to definitively demonstrate that renal sympathetic tone was normal in older men.
The lowered epinephrine secretion rate with aging, accompanied by sympathetic nervous system activation, emphasizes that the two elements of the "sympathoadrenal medullary system" do not always act in concert, so that a mismatching of sympathetic activity and epinephrine secretion rate can occur. Two other examples, of several, are the increased epinephrine secretion accompanying sympathetic inhibition that is present in both fasting and vasovagal syncope (19). Whether any functional disability is conveyed by reduced epinephrine secretion in the elderly is not clear. Epinephrine secretion with mental stress and with aerobic and isometric exercise are also reduced in the elderly (13), but it is not known if this contributes to observed reductions in vigilance and exercise capacity accompanying aging.
The functional significance of the sympathetic nervous activation with aging is also problematic, although potentially of importance. The impetus for continuing interest in this topic has come in part from the recognition that in a range of cardiovascular disorders, including essential hypertension, cardiac failure, and ventricular arrhythmias, for all of which incidence rises markedly with age, sympathetic nervous system pathophysiology may be an important causal component (11).
A statistically significant direct relationship existed between subcortical norepinephrine turnover and sympathetic tone in the cardiac and hepatomesenteric sympathetic outflows. Sympathoexcitatory projections from regions such as the locus ceruleus and A5 region of the brain stem to the hypothalamus and amygdala are important in the central regulation of sympathetic outflow (20, 35), and caudal projections from the hypothalamus are known to be of importance in the sympathetic regulation of the hepatic circulation (34). Our results here in humans, in which with aging neuronal norepinephrine turnover was increased in a field of brain subcortical venous drainage that excludes the medulla oblongata (18), are in agreement with experimental studies in animals, which indicate that the baroreflex-related noradrenergic bulbar inhibition of sympathetic outflow, although important, can be overridden by stimulatory suprabulbar noradrenergic mechanisms, of which rostral projections to the hypothalamus are among the most important (20, 35). Independent observations made in parallel to the present study provide further evidence that the sympathetic activation of human aging is not generated by the arterial baroreflex (5).
In summary, we document increased turnover of norepinephrine in subcortical areas of the brain, in company with activation of the sympathetic outflows to the heart and hepatomesenteric circulation, with human aging. The findings suggest that noradrenergic neuronal projections to the suprabulbar subcortical areas produce the sympathetic nervous activation characteristic of healthy aging, a mechanism that also appears to underlie the sympathetic activation present in heart failure and essential hypertension.
Limitations
Although differentiating the pattern of cerebral drainage into the internal jugular veins was of crucial importance in the present study in allowing selective measurement of suprabulbar subcortical norepinephrine turnover, our methodology does not have the topographic precision to allow study of specific brain nuclei or their projections. In the future, brain imaging techniques may possibly acquire the specificity and precision to quantify highly regionalized monoamine neurotransmitter turnover in this way, but at present this capacity does not exist. Magnetic resonance imaging can be applied to measure regional blood flow and oxygen utilization but cannot give specific information on neuronal monoamine release. Positron emission tomography (PET) using 18-F dopamine can be applied to the study of norepinephrine turnover in sympathetic nerves (17), but no suitable PET agents for studying norepinephrine turnover in the human brain are available. The deficiency of a lack of topographical detail with our technique for measuring brain monoamine turnover to some extent was overcome in the present study by ascertaining the separate origins of cerebral drainage into the right and left internal jugular veins, to allow selective measurement of suprabulbar subcortical and cortical norepinephrine turnover (6, 22).Perspectives
Activation of the sympathetic nervous system is one of the cardinal pathophysiological features of essential hypertension (29-31). Until now it has been surmised that stimulation of sympathetic nervous outflows to organs involved in blood pressure regulation with aging is a causal mechanism of hypertension in the elderly. The present study provides evidence, however, that this scenario is improbable on two counts.First, hypertension in the elderly, in fact, is typically not accompanied by sympathetic nervous system activation above a level seen in elderly people with normal blood pressure (9). Increased resting sympathetic tone is much more typical of hypertension in young and middle-aged adults (1, 25, 29-31).
Second, the pattern of sympathetic nervous and adrenal medullary changes in hypertension and aging differ markedly. The sympathetic nervous activation present in essential hypertension involves the renal sympathetic nerves, which appears to be crucial in hypertension pathogenesis (6, 12), spares the hepatomesenteric circulation, and is accompanied by normal adrenal medullary secretion of adrenaline (25, 29-31). None of these apply to aging, in which epinephrine secretion is reduced and the sympathetic outflow to the kidneys appears to be normal, whereas that to the hepatomesenteric circulation is increased (15, 19, 36).
| |
ACKNOWLEDGEMENTS |
|---|
This work was supported by United States Public Health Service, National Institute on Aging Grant RO1 AG-06537-07 and a National Health and Medical Research Council of Australia Institute grant to the Baker Medical Research Institute.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: M. Esler, Baker Medical Research Institute, PO Box 6492, St. Kilda Road Central, Melbourne, Victoria 8008, Australia (E-mail: murray.esler{at}baker.edu.au).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
10.1152/ajpregu.00335.2001
Received 12 June 2001; accepted in final form 12 November 2001.
| |
REFERENCES |
|---|
|
|
|---|
1.
Anderson, EA,
Sinkey CA,
Lawton WJ,
and
Mark AL.
Elevated sympathetic nerve activity in borderline hypertensive humans.
Hypertension
14:
177-183,
1989
2.
Aneman, A,
Eisenhofer G,
Fandriks,
and
Friberg P.
Hepatomesenteric release and removal of norepinephrine in swine.
Am J Physiol Regulatory Integrative Comp Physiol
268:
R924-R930,
1995
3.
Aneman, A,
Eisenhofer G,
Olbe L,
Dalenback J,
Nitescu P,
Fandriks L,
and
Friberg P.
Sympathetic discharge to mesenteric organs and the liver. Evidence for substantial mesenteric organ norepinephrine spillover.
J Clin Invest
97:
1640-1646,
1996[ISI][Medline].
4.
Chalmers, J,
and
Pilowsky P.
Brainstem and bulbospinal neurotransmitter system in the control of blood pressure.
J Hypertens
9:
675-694,
1991[ISI][Medline].
5.
Davy, KP,
Tanaka H,
Andros EA,
Gerber JG,
and
Seals DR.
Influence of age on baroreflex inhibition of sympathetic nerve activity in healthy adult humans.
Am J Physiol Heart Circ Physiol
275:
H1768-H1772,
1998
6.
Di Bona, GF.
Sympathetic neural control of the kidney in hypertension.
Hypertension
19:
I-28-I-35,
1992.
7.
Eisenhofer, G,
Friberg P,
Rundqvist B,
Quyyumi AA,
Lambert G,
Kaye DM,
Kopin IJ,
Goldstein DS,
and
Esler MD.
Cardiac sympathetic nerve function in congestive heart failure.
Circulation
93:
1667-1676,
1996
8.
Eisenhofer, G,
Goldstein DS,
Ropchak TG,
Nguyen HQ,
Keiser HR,
and
Kopin IJ.
Sources and physiological significance of plasma 3,4-dihydroxyphenylglycol and 3-methoxy-4-hydroxyphenyglycol.
J Auton Nerv Syst
24:
1-14,
1988[ISI][Medline].
9.
Esler, M,
Jennings G,
Biviano B,
Lambert G,
and
Hasking G.
Mechanism of elevated plasma noradrenaline in the course of essential hypertension.
J Cardiovasc Pharmacol
8, Suppl5:
539-544,
1986[ISI][Medline].
10.
Esler, M,
Jennings G,
Lambert G,
Meredith I,
Horne M,
and
Eisenhofer G.
Overflow of catecholamine neurotransmitters to the circulation: source, fate and functions.
Physiol Rev
70:
963-985,
1990
11.
Esler, M,
and
Kaye D.
Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease.
J Cardiovasc Pharmacol
35, Suppl4:
S1-S7,
2000[ISI][Medline].
12.
Esler, M,
Rumantir M,
Kaye D,
and
Lambert G.
The sympathetic neurobiology of essential hypertension: disparate influences of obesity, stress and noradrenaline transporter dysfunction?
Am J Hypertens
14:
139S-146S,
2001[ISI][Medline].
13.
Esler, MD,
Kaye DM,
Thompson JM,
Jennings GL,
Cox HS,
Turner AG,
Lambert GW,
and
Seals DR.
Effects of aging on epinephrine secretion, and on regional release of epinephrine from the human heart.
J Clin Endocrinol Metab
80:
435-442,
1995[Abstract].
14.
Esler, MD,
Thompson JM,
Kaye DM,
Turner AG,
Jennings GL,
Cox HS,
Lambert GW,
and
Seals DR.
Effects of aging on the responsiveness of the human cardiac sympathetic nerves to stressors.
Circulation
91:
351-358,
1995
15.
Esler, MD,
Turner AG,
Kaye DM,
Thompson JM,
Kingwell BA,
Morris M,
Lambert GW,
Jennings GL,
Cox HS,
and
Seals DR.
Effects of aging on the human sympathetic nervous system at rest studied using neurochemical indices of neuronal function.
Am J Physiol Regulatory Integrative Comp Physiol
268:
R278-R285,
1995
16.
Ferrier, C,
Jennings GL,
Eisenhofer G,
Lambert G,
Cox HS,
Kalff V,
Kelly M,
and
Esler MD.
Evidence for increased noradrenaline release from subcortical brain regions in essential hypertension.
J Hypertens
11:
1217-1227,
1993[ISI][Medline].
17.
Goldstein, DS,
Holmes C,
Cannon RO, III,
Eisenhofer G,
and
Kopin IJ.
Sympathetic cardioneuropathy in dysautonomias.
N Engl J Med
336:
696-702,
1997
18.
Gray, H.
Angiology and neurology.
In: Gray's Anatomy (36th ed.), edited by Williams PL,
and Warwick R.. Edinburgh: Churchill Livingston, 1980, p. 622-1216.
19.
Grassi, M,
and
Esler M.
How to assess sympathetic activity in humans.
J Hypertens
17:
719-734,
1999[ISI][Medline].
20.
Huangfu, DH,
Koshiya N,
and
Guyenet PG.
A5 noradrenergic unit activity and sympathetic nerve discharge in rats.
Am J Physiol Regulatory Integrative Comp Physiol
261:
R393-R402,
1991
21.
Lambert, G,
Johansson M,
Agren H,
and
Friberg P.
Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness.
Arch Gen Psychiatry
57:
787-793,
2000
22.
Lambert, GW,
Ferrier C,
Kaye D,
Cox HS,
Turner AG,
Jennings GL,
and
Esler MD.
Monoaminergic neuronal activity in subcortical brain regions in essential hypertension.
Blood Press
3:
55-66,
1994[Medline].
23.
Lambert, GW,
Kaye DM,
Lefkovits J,
Jennings GL,
Turner AG,
Cox HS,
and
Esler MD.
Central nervous system monoamine neurotransmitter turnover and its association with sympathetic nervous activity in treated heart failure patients.
Circulation
92:
1813-1818,
1995
24.
Lambert, GW,
Kaye DM,
Thompson JM,
Turner AG,
Cox HS,
Vaz M,
Jennings GL,
Wallin BG,
and
Esler MD.
Internal jugular venous spillover of noradrenaline and metabolites and their association with sympathetic nervous activity.
Acta Physiol Scand
163:
155-163,
1998[ISI][Medline].
25.
Lambert, GW,
Kaye DM,
Vaz M,
Cox HS,
Turner AG,
Jennings GL,
and
Esler MD.
The influence of sympathetic nervous system activation on the regional production of 3-methoxy-4-hydroxyphenylglycol in humans.
J Auton Nerv Syst
55:
169-178,
1995[ISI][Medline].
26.
Lambert, GW,
Vaz M,
Cox HS,
Turner AG,
Kaye DM,
Jennings GL,
and
Esler MD.
Human obesity is associated with a chronic elevation in brain 5-hydroxytryptamine turnover.
Clin Sci (Lond)
96:
191-197,
1999[Medline].
27.
Medvedev, OS,
Esler MD,
Angus JA,
Cox HS,
and
Eisenhofer G.
Simultaneous determination of plasma noradrenaline and adrenaline kinetics: responses to nitroprusside-induced hypotension and 2-deoxyglucose-induced glucopenia in the rabbit.
Naunyn Schmiedebergs Arch Pharmacol
341:
192-199,
1990[ISI][Medline].
28.
Ng, AV,
Callister R,
Johnson DG,
and
Seals DR.
Age and gender influence muscle sympathetic nerve activity at rest in healthy humans.
Hypertension
21:
498-503,
1993
29.
Rumantir, MS,
Jennings GL,
Lambert GW,
Kaye DM,
Seals DR,
and
Esler MD.
The "adrenaline hypothesis" of hypertension revisited: evidence for adrenaline release from the heart of patients with essential hypertension.
J Hypertens
18:
717-723,
2000[ISI][Medline].
30.
Rumantir, MS,
Kaye DM,
Jennings GL,
Vaz M,
Hastings JA,
and
Esler MD.
Phenotypic evidence of faulty neuronal noradrenaline reuptake in essential hypertension.
Hypertension
36:
824-829,
2000
31.
Rumantir, MS,
Vaz M,
Jennings GL,
Collier G,
Kaye DM,
Seals DR,
Wiesner GH,
Brunner-La Rocca HP,
and
Esler MD.
Neural mechanisms in human obesity-related hypertension.
J Hypertens
17:
1125-1133,
1999[ISI][Medline].
32.
Seals, DR,
and
Esler MD.
Topical review: human ageing and the sympathoadrenal system.
J Physiol (Lond)
528:
407-417,
2000
33.
Snedecor, GW,
and
Cochrane WG
Statistical Methods (6th ed.). Ames, IA: Iowa State University Press, 1967.
34.
Tysbenko, VA,
and
Yanchuk PI.
Central nervous control of hepatic circulation.
J Auton Nerv Syst
33:
255-266,
1991[ISI][Medline].
35.
Van Huysse, JW,
and
Bealer SL.
Central nervous system norepinephrine release, hypotension and hyperosmolality in conscious rats.
Am J Physiol Regulatory Integrative Comp Physiol
260:
R1071-R1076,
1991
36.
Veith, RC,
Featherstone JA,
Linares OA,
and
Halter JB.
Age differences in plasma norepinephrine kinetics in humans.
J Gerontol
41:
319-324,
1986[ISI][Medline].
37.
Yamada, Y,
Miyajima E,
Tochikubo O,
Matsukawa T,
and
Ishii M.
Age-related changes in muscle sympathetic nerve activity in essential hypertension.
Hypertension
13:
870-877,
1989
This article has been cited by other articles:
![]() |
M. H. Pennestri, J. Montplaisir, R. Colombo, G. Lavigne, and P. A. Lanfranchi Nocturnal blood pressure changes in patients with restless legs syndrome Neurology, April 10, 2007; 68(15): 1213 - 1218. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Nelson and G. A. Iwamoto Reversibility of exercise-induced dendritic attenuation in brain cardiorespiratory and locomotor areas following exercise detraining J Appl Physiol, October 1, 2006; 101(4): 1243 - 1251. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. Mayer, C. Schroeder, K. Heusser, J. Tank, A. Diedrich, R. E. Schmieder, F. C. Luft, and J. Jordan Influences of Norepinephrine Transporter Function on the Distribution of Sympathetic Activity in Humans Hypertension, July 1, 2006; 48(1): 120 - 126. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Gould, M. Yii, M. D. Esler, J. M. Power, and D. M. Kaye Atrial fibrillation impairs cardiac sympathetic response to baroreceptor unloading in congestive heart failure Eur. Heart J., December 1, 2005; 26(23): 2562 - 2567. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Seals and F. A. Dinenno Collateral damage: cardiovascular consequences of chronic sympathetic activation with human aging Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H1895 - H1905. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. A. Koomans, P. J. Blankestijn, and J. A. Joles Sympathetic Hyperactivity in Chronic Renal Failure: A Wake-up Call J. Am. Soc. Nephrol., March 1, 2004; 15(3): 524 - 537. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Seals and C. Bell Chronic Sympathetic Activation: Consequence and Cause of Age-Associated Obesity? Diabetes, February 1, 2004; 53(2): 276 - 284. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |